Literature DB >> 15841889

Growth and quality of the cost-utility literature, 1976-2001.

Peter J Neumann1, Dan Greenberg, Natalia V Olchanski, Patricia W Stone, Allison B Rosen.   

Abstract

PURPOSE: Cost-utility analyses (CUAs) have become increasingly popular, although questions persist about their comparability and credibility. Our objectives were to: 1) describe the growth and characteristics of CUAs published in the peer-reviewed literature through 2001; 2) investigate whether CUA quality has improved over time; 3) examine whether quality varies by the experience of journals in publishing CUAs, or the source of external funding for study investigators; and 4) examine changes in practices in US-based studies following recommendations of the US Panel on Cost-Effectiveness in Health and Medicine (USPCEHM). This study updates and expands our previous work, which examined CUAs through 1997.
METHODS: We conducted a systematic search of the English-language medical literature for original CUAs published from 1976 through 2001, using Medline and other databases. Each study was audited independently by two trained readers, who recorded the methodological and reporting practices used.
RESULTS: Our review identified 533 original CUAs. Comparing articles published in 1998 to 2001 (n = 305) with those published in 1976 to 1997 (n = 228), studies improved in almost all categories, including: clearly presenting the study perspective (73% vs. 52%, P < 0.001); discounting both costs and quality-adjusted life-years (82% vs. 73%, P = 0.0115); and reporting incremental cost-utility ratios (69% vs. 46%, P < 0.001). The proportion of studies disclosing funding sources did not change (65% vs. 65%, P = 0.939). Adherence to recommended practices was greater in more experienced journals, and roughly equal in industry versus non-industry-funded analyses. The data suggest an impact in methodological practices used in US-based CUAs in accordance with recommendations of the USPCEHM.
CONCLUSIONS: Adherence to methodological and reporting practices in published CUAs is improving, although many studies still omit basic elements. Medical journals, particularly those with little experience publishing cost-effectiveness analyses, should adopt and enforce standard protocols for conducting and reporting CUAs.

Mesh:

Year:  2005        PMID: 15841889     DOI: 10.1111/j.1524-4733.2005.04010.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  47 in total

Review 1.  The cost-effectiveness of biopharmaceuticals: a look at the evidence.

Authors:  Andrew W Wilson; Peter J Neumann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  A comparison of the ICECAP-O with EQ-5D in a falls prevention clinical setting: are they complements or substitutes?

Authors:  Jennifer C Davis; Teresa Liu-Ambrose; Chris G Richardson; Stirling Bryan
Journal:  Qual Life Res       Date:  2012-06-22       Impact factor: 4.147

3.  Utilities and QALYs in health economic evaluations: glossary and introduction.

Authors:  Gianni Virgili; Daniela Koleva; Livio Garattini; Rita Banzi; Gian Franco Gensini
Journal:  Intern Emerg Med       Date:  2010-07-06       Impact factor: 3.397

4.  Use of economic evaluation in decision making: evidence and recommendations for improvement.

Authors:  Steven Simoens
Journal:  Drugs       Date:  2010-10-22       Impact factor: 9.546

5.  Measuring preferences for cost-utility analysis: how choice of method may influence decision-making.

Authors:  Christine M McDonough; Anna N A Tosteson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 6.  A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?

Authors:  Tracey H Sach; Richard D Smith; David K Whynes
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 7.  Economic evaluations of cholesterol-lowering drugs: a critical and systematic review.

Authors:  Pearl D Gumbs; Monique W M Verschuren; Aukje K Mantel-Teeuwisse; Ardine G de Wit; Anthonius de Boer; Olaf H Klungel
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 8.  Bias in published cost effectiveness studies: systematic review.

Authors:  Chaim M Bell; David R Urbach; Joel G Ray; Ahmed Bayoumi; Allison B Rosen; Dan Greenberg; Peter J Neumann
Journal:  BMJ       Date:  2006-02-22

Review 9.  Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.

Authors:  Sun-Young Kim; Sue J Goldie
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 10.  When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology.

Authors:  Dan Greenberg; Craig Earle; Chi-Hui Fang; Adi Eldar-Lissai; Peter J Neumann
Journal:  J Natl Cancer Inst       Date:  2010-01-07       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.